Pantarhei Bioscience BV (PRB) is a bio-pharmaceutical company located in the Netherlands that develops unique new treatment concepts for Women’s Health.
The product pipeline is based on Pantarhei’s ability to identify novel medical uses of existing targets, hormones, biologicals, drugs or combinations thereof in these areas of medicine. The main areas of expertise of PRB are hormonal contraception and menopausal hormone therapy as well as reproductive hormone related treatments and diseases.
PRB has founded its subsidiary company Pantarhei Oncology BV (PRO) in 2014 for the development of reproductive endocrine oncology (REO) applications. The main areas of expertise of PRO are breast cancer, prostate cancer and ovarian cancer.
The business model of PRB is based on creating intellectual property (IP) for new treatment concepts and providing in-house project management. All research and development activities are outsourced. PRB develops patent protected treatments up to phase II efficacy and safety. Using existing molecules provides first evidence of safety. After generating favourable and safe human proof-of-concept data, projects are sold or licensed-out to a (pharmaceutical) partner for final development (phase III), regulatory approval and commercialisation. Over the years, Pantarhei has sold and licensed a series of unique treatment concepts.